A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
- Registration Number
- NCT02783573
- Lead Sponsor
- AstraZeneca
- Brief Summary
The main purpose of this study is to evaluate the efficacy of the study drug known as lanabecestat in participants with mild Alzheimer's disease (AD) dementia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 1722
- Participant must meet the National Institute on Aging (NIA) and the Alzheimer's Association (AA) (NIA-AA) criteria for probable AD dementia.
- MMSE score of 20 to 26 inclusive at screening visit.
- For a diagnosis of mild AD dementia, participant must have a CDR global score of 0.5 or 1, with the memory box score ≥0.5 at screening.
- Evidence of amyloid pathology.
- The participant must have a reliable study partner with whom he/she cohabits or has regular contact.
- Significant and/or current neurological disease affecting the central nervous system, other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, repetitive head trauma, serious infection of the brain, Parkinson's disease, epilepsy, or cervicocranial vascular disease.
- Participants with any current primary psychiatric diagnosis other than AD if, in the judgment of the investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessment, or affect the participant's ability to complete the study. Participants with history of schizophrenia or other chronic psychosis are excluded.
- Within 1 year before the screening visit or between screening and randomization, any of the following: myocardial infarction; moderate or severe congestive heart failure, New York Heart Association class III or IV; hospitalization for, or symptoms of, unstable angina; syncope due to orthostatic hypotension or unexplained syncope; known significant structural heart disease (such as, significant valvular disease, hypertrophic cardiomyopathy); or hospitalization for arrhythmia.
- Congenital QT prolongation.
- Intermittent second- or third-degree atrioventricular (AV) heart block or AV dissociation or history of ventricular tachycardia.
- A corrected QT (QTcF) interval measurement >470 milliseconds (men and women) at screening (as determined at the investigational site).
- History of malignant cancer within the last 5 years.
- History of vitiligo and/or current evidence of post-inflammatory hypopigmentation.
- Calculated creatinine clearance <30 milliliters per minute (Cockcroft-Gault formula; Cockcroft and Gault 1976) at screening.
- Currently enrolled in any other clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo/ Lanabecestat 50 mg Lanabecestat Placebo given orally once daily for 78 weeks and then 50 mg of lanabecestat given orally once daily until week 156. Placebo/ Lanabecestat 20 mg Lanabecestat Placebo given orally once daily for 78 weeks and then 20 mg of lanabecestat given orally once daily until week 156. Placebo/ Lanabecestat 20 mg Placebo Placebo given orally once daily for 78 weeks and then 20 mg of lanabecestat given orally once daily until week 156. Placebo/ Lanabecestat 50 mg Placebo Placebo given orally once daily for 78 weeks and then 50 mg of lanabecestat given orally once daily until week 156. Lanabecestat 50 mg Lanabecestat Participants received Lanabecestat 50 mg film-coated tablets orally once daily until week 156. Lanabecestat 20 milligrams (mg) Lanabecestat Participants received Lanabecestat 20 mg film-coated tablets orally once daily until week 156.
- Primary Outcome Measures
Name Time Method Change From Baseline in Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog13) Score Baseline, Week 78 ADAS-Cog13 (13-item version of ADAS Cog) is a psychometric instrument that evaluates word recall, ability to follow commands, constructional praxis, naming, ideational praxis, orientation, word recognition, memory, comprehension of spoken language, word-finding, and language ability, with a measure of delayed word recall and concentration/ distractibility. The total score of the 13-item scale ranges from 0 to 85, with an increase in score indicating cognitive worsening. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with factors for treatment, visit, treatment-by-visit interaction, acetylcholinesterase Inhibitor (AChEI) use at baseline, pooled site, and covariates for baseline ADAS-Cog13 total score, age at baseline, and baseline ADAS-Cog13 total score-by-visit interaction.
- Secondary Outcome Measures
Name Time Method Change From Baseline in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score Baseline, Week 78 The CDR-SB is a rater administered scale and impairment is scored in each of categories: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care. Impairment is scored on a scale in which no dementia = 0, questionable dementia = 0.5, mild dementia = 1, moderate dementia = 2 and severe dementia = 3. The 6 individual category ratings, or "box scores", were added together to give the CDR-Sum of Boxes which ranges from 0-18, with higher scores indicating greater impairment. LS Mean was determined by MMRM methodology with factors for treatment, visit, treatment-by-visit interaction, AChEI use at baseline, pooled site, and covariates for baseline CDR-SB score, age at baseline, and baseline CDR-SB score-by-visit interaction.
Change From Baseline in Regional Cerebral Blood Flow (rCBF) Using Florbetapir Perfusion Scan Baseline, Week 78 Florbetapir perfusion evaluated the regional cerebral blood flow (rCBF) as a biomarker of brain function and was performed at the same time as the amyloid florbetapir PET. Cerebral perfusion, especially in temporal and parietal areas, is reduced in AD and this pattern of hypoperfusion closely mirrors the hypometabolism pattern observed using FDG PET. Annualized change is derived as change at LOCF divided by (LOCF date - baseline date) multiplied by 365. LS Mean was determined by ANCOVA with LOCF (last observation carried forward) and with factors for treatment, baseline biomarker and age at baseline.
Change From Baseline in Alzheimer´s Disease Cooperative Study Activities of Daily Living Inventory Instrumental Items Score (ADCS-iADL) Baseline, Week 78 The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities of daily living by participants. The range for the ADCS-iADL is 0-59 with higher scores reflecting better performance. LS Mean was determined by MMRM model with factors for treatment, visit, treatment-by-visit interaction, AChEI use at baseline, pooled site, and covariates for baseline iADL score, age at baseline, and baseline iADL score-by-visit interaction.
Change From Baseline in Functional Activities Questionnaire (FAQ) Score Baseline, Week 78 FAQ is a 10-item, caregiver-based questionnaire and was administered to the study partner who was asked to rate the participant's ability to perform a variety of activities ranging from writing checks, assembling tax records, shopping, playing games, food preparation, traveling, keeping appointments, traveling out of neighborhood, keeping track of current events and understanding media. FAQ total score was calculated by adding the scores from each of the 10 items. Each activity is rated on a scale from 0 to 3 (Never did and would have difficulty now=1; never did \[the activity\] but could do now=0; normal=0; has difficulty but does by self=1; requires assistance=2; Dependent =3). FAQ scale is 0 to 30, with higher scores indicating greater impairment. LS Mean determined by MMRM model with factors for treatment, visit, treatment-by-visit interaction, AChEI use at baseline, pooled site, and covariates for baseline FAQ total score, by-visit interaction and age at baseline.
Time to Progression as Measured by Loss of Clinical Dementia Rating (CDR) Global Score Stage From Loss of 1 Global Stage through Week 78 The CDR global score is a composite score calculated using the Washington University CDR-assignment algorithm applied to the 6 individual domain box scores (Morris 1993). The memory domain is considered the primary category that drives the CDR global outcome, and all other domains are secondary. The CDR global score ranges from 0 to 3 (0 = no dementia, 0.5 = questionable dementia, 1 = mild dementia, 2 = moderate dementia, 3 = severe dementia).
Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) Score Baseline, Week 78 The iADRS is a composite that measures both cognition and function. The iADRS comprises scores form the ADAS- Cog and the ADCS-iADL. The iADRS is calculated as a linear combination of the total scores of the ADAS-Cog13 (score range 0 to 85 with higher scores reflecting worse performance) and the ADCS-iADL (score range from 0-59 with higher scores reflecting better performance). The iADRS score ranges from 0 to 144 with higher scores indicating greater impairment. LS Mean was determined by MMRM with factors for treatment, visit, treatment-by-visit interaction, AChEI use at baseline, pooled site, and covariates for baseline iADRS13 total score, age at baseline, and baseline iADRS13 total score-by-visit interaction.
Change From Baseline in Neuropsychiatric Inventory (NPI) Score Baseline, Week 78 The NPI is a questionnaire administered to caregivers that quantifies behavioral changes. Each of the 12 behavioral domains the caregiver reports as present are scored for Frequency, scale: 1 (Occasionally) to 4 (Very Frequently), and Severity, scale: 1 (Mild) to 3 (Severe). If the domain is reported by the caregiver as 'Not Affected,' that domain is scored as 0. The individual domain scores are calculated by multiplying the frequency times the severity for each domain. NPI Total Score is calculated by adding the individual domain scores together for all 12 domains, with a scores range from 0 to 144, with higher scores indicating a greater severity of neuropsychiatric disturbance. LS Mean was determined by MMRM methodology with factors for treatment, visit, treatment-by-visit interaction, AChEI use at baseline, pooled site, and covariates for baseline NPI score, age at baseline, and baseline NPI score-by-visit interaction.
Change From Baseline in CSF Biomarker Total Tau Baseline, Week 71 Cerebrospinal fluid samples were collected for analysis of concentration total tau. LS Mean was determined by ANCOVA with LOCF and with factors for treatment, baseline biomarker and age at baseline.
Population Pharmacokinetics (PK): Apparent Oral Clearance of Lanabecestat Predose, Week 4, 7, 19, 39, 45 and Week 71 post dose The apparent oral clearance of lanabecestat was estimated using a population approach. No covariate effects were assessed as part of this analysis.
Change From Baseline on the Mini-Mental State Examination (MMSE) Baseline, Week 78 The MMSE is an instrument used to assess a participant's global cognitive function. The MMSE assesses orientation to time and place, immediate and delayed recall of words, attention and calculation, language (naming, comprehension and repetition), and spatial ability (copying a figure). The range for MMSE total Score is 0 to 30, with a higher score indicating better cognitive performance. LS Mean was determined by MMRM methodology with factors for treatment, visit, treatment-by-visit interaction, AChEI use at baseline, pooled site, and covariates for baseline MMSE total score, age at baseline, and baseline MMSE total score-by-visit interaction.
Percent Change From Baseline in Concentration of CSF Biomarker Aβ1-40 Baseline, Week 71 Concentration of the peptide Aβ 1-40 in plasma measured by immunoassay. LS Mean was determined by ANCOVA with LOCF (last observation carried forward), terms for treatment, baseline biomarker and age at baseline.
Change From Baseline in CSF Biomarker Phosphorylated Tau Baseline, Week 71 Cerebrospinal fluid samples are collected for analysis of concentration of phosphorylated tau. LS Mean was determined by ANCOVA with LOCF and with factors for treatment, baseline biomarker and age at baseline.
Change From Baseline in Whole Brain Volume Baseline, Week 78 Magnetic resonance imaging (MRI) was used to evaluate the effect of lanabecestat on brain atrophy/whole brain volumes. Annualized change is derived as change at LOCF divided by (LOCF date - baseline date) multiplied by 365. LS Mean was determined by ANCOVA with LOCF and with factors for treatment, baseline volumetric magnetic resonance imaging (vMRI), intracranial volume and age at baseline.
Population PK: Central Volume of Distribution of Lanabecestat Predose, Week 4, 7, 19, 39, 45 and week 71 post dose The central volume of distribution for lanabecestat was estimated using a population approach. No covariate effects were assessed as part of this analysis.
Percent Change From Baseline in Concentration of Cerebrospinal Fluid (CSF) Biomarker Amyloid Beta (Aβ)1-42 Baseline, Week 71 Concentration of the peptide Aβ 1-42 in plasma measured by validated immunoassay. LS Mean was determined by Analysis of covariance (ANCOVA) with last observation carried forward (LOCF), terms for treatment, baseline biomarker and age at baseline.
Change From Baseline in Brain Amyloid Burden Using Florbetapir Amyloid Positron Emission Tomography (PET) Scan Baseline, Week 78 Amyloid deposition in the brain is one of the defining neuropathologic findings of Alzheimer's disease. Florbetapir exhibits high affinity specific binding to amyloid plaques. The change from baseline was measured as average standard uptake value ratio (SUVr) in prespecified regions of interest (ROI) assessed by florbetapir amyloid PET imaging in a subset of participants. The Centiloid scale standardizes quantitative brain amyloid PET results to allow cross-tracer and cross-methodology comparisons. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scans. Florbetapir SUVr was converted to the Centiloid scale using the following conversion: Florbetapir Centiloids = 183 x SUVr - 177. LS Mean was determined by using ANCOVA methodology with terms for treatment, baseline biomarker and age at baseline.
Trial Locations
- Locations (257)
Maine Neurology
🇺🇸Scarborough, Maine, United States
Eastern Maine Medical Center
🇺🇸Bangor, Maine, United States
Atlanta Center of Medical Research
🇺🇸Atlanta, Georgia, United States
Care Access Research
🇺🇸Valencia, California, United States
California Neuroscience Research
🇺🇸Sherman Oaks, California, United States
Emory University
🇺🇸Atlanta, Georgia, United States
Medical Research Health and Education Foundation, Inc
🇺🇸Columbus, Georgia, United States
Raleigh Neurology Associates
🇺🇸Raleigh, North Carolina, United States
Ohio State University Medical Center
🇺🇸Columbus, Ohio, United States
Xenoscience
🇺🇸Phoenix, Arizona, United States
California Research Foundation
🇺🇸San Diego, California, United States
Pacific Research Network Inc
🇺🇸San Diego, California, United States
Sharp Mesa Vista Hospital
🇺🇸San Diego, California, United States
University of Miami
🇺🇸Miami, Florida, United States
Allied Biomedical Research Institute, Inc.
🇺🇸Miami, Florida, United States
Josephson Wallack Munshower Neurology
🇺🇸Indianapolis, Indiana, United States
Boston University Medical Center
🇺🇸Boston, Massachusetts, United States
Texas Medical Research Associates, L.L.C.
🇺🇸San Antonio, Texas, United States
Chu De Nancy Hop D'Adultes De Brabois
🇫🇷Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France
Mayo Clinic-Jacksonville
🇺🇸Jacksonville, Florida, United States
Gregory A. Kirk MD LLC
🇺🇸Merritt Island, Florida, United States
Donald S Marks
🇺🇸Plymouth, Massachusetts, United States
Kawartha Regional Memory Clinic
🇨🇦Peterborough, Ontario, Canada
Neuropsychiatric Research Center of Southwest Florida
🇺🇸Fort Myers, Florida, United States
Four Peaks Neurology
🇺🇸Scottsdale, Arizona, United States
Quantum Laboratories
🇺🇸Pompano Beach, Florida, United States
Alzheimers Disease Center
🇺🇸Winchester, Massachusetts, United States
Research Center for Clinical Studies, Inc
🇺🇸Norwalk, Connecticut, United States
Brain Matters Research
🇺🇸Delray Beach, Florida, United States
Ericksen Research and Development
🇺🇸Clinton, Utah, United States
Klinikum der Universität München
🇩🇪München, Bayern, Germany
Policlinico Univ. Agostino Gemelli
🇮🇹Roma, Lazio, Italy
Himuro Neurology Clinic
🇯🇵Osaka-Shi, Osaka-Fu, Japan
Ikeuchi Psycho Induced Internal Clinic
🇯🇵Kobe-shi, Japan
Clinical Research Institute S C
🇲🇽Tlalnepantla, Edo De Mex, Mexico
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Neurozentrum Sophienstraße
🇩🇪Stuttgart, Baden-Württemberg, Germany
Cohen Medical Associates P.A.
🇺🇸Delray Beach, Florida, United States
Memory Clinic Ochanomizu
🇯🇵Bunkyo-ku, Tokyo, Japan
Aomori Prefectural Centeral Hospital
🇯🇵Aomori, Japan
RSBIH Smolensk Regional Clinical Hospital
🇷🇺Smolensk, Russian Federation
Intercoastal Medical Group
🇺🇸Sarasota, Florida, United States
Charlton Lane Hospital
🇬🇧Cheltenham, Gloucestershire, United Kingdom
True North Clinical Research Halifax, LLC
🇨🇦Halifax, Nova Scotia, Canada
Institut Claude Pompidou - CMRR
🇫🇷Nice, Alpes Maritimes, France
Toronto Sunnybrook Regional Cancer Center
🇨🇦Toronto, Ontario, Canada
Klinikum Rechts der Isar der TU München
🇩🇪München, Bayern, Germany
Dong-A University Medical Center
🇰🇷Busan, Busan Gwang'yeogsi, Korea, Republic of
The Catholic University of Korea-Bucheon St. Mary's Hospital
🇰🇷Bucheon-si, Gyeonggi-do, Korea, Republic of
Myongji Hospital
🇰🇷Goyang-si, Gyeonggi-do, Korea, Republic of
Mexico Centre for Clinical Research SA de CV
🇲🇽Mexico City, Distrito Federal, Mexico
FSBIH Siberian Clinical Center of FMBA
🇷🇺Krasnoyarsk, Russian Federation
Ultramed
🇷🇺Omsk, Russian Federation
Michigan State University
🇺🇸East Lansing, Michigan, United States
University of Calgary
🇨🇦Calgary, Alberta, Canada
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
CSSS-Institut Universitaire Gériatric de Sherbrooke
🇨🇦Sherbrooke, Qubec, Canada
SDN - Istituto di Ricerca Diagnostica e Nucleare
🇮🇹Napoli, Italy
Nara Medical University Hospital
🇯🇵Kashihara, Nara, Japan
Kotobukikai Tominaga Clinic
🇯🇵Osaka-shi, Osaka-Fu, Japan
NHO Hizen Psychiatric Center
🇯🇵Kanzaki-gun, Saga-Ken, Japan
Juntendo University Hospital
🇯🇵Bunkyo-ku, Tokyo, Japan
NHO Niigata Hospital
🇯🇵Niigata, Japan
NHO Hokkaido Medical Center
🇯🇵Sapporo-shi, Japan
EB Utrecht
🇳🇱Utrecht, Netherlands
Konkuk University Hospital
🇰🇷Seoul, Korea, Republic of
Praxis für Neurologie und Psychiatrie Dr. med. Roth
🇩🇪Ostfildern, Baden-Württemberg, Germany
IRCCS Azienda Ospedaliera Universitaria San Martino
🇮🇹Genova, Italy
Katayama Medical Clinic
🇯🇵Kurashiki-shi, Okayama-Ken, Japan
Hospital Universitario de Saltillo
🇲🇽Saltillo, Coahuila, Mexico
NZOZ Wroclawskie Centrum Alzheimerowskie
🇵🇱Wroclaw, Dolnoslaskie, Poland
Uniwersyteckie Centrum Kliniczne
🇵🇱Gdansk, Pomorskie, Poland
Klinika Neurologii Neuro-Care
🇵🇱Katowice, Poland
Changhua Christian Hospital
🇨🇳Changhua, Taiwan
Avix Investigación Clínica, S.C
🇲🇽Monterrey, Nuevo León, Mexico
Instituto de Informacion en Salud Mental (INFOSAM)
🇲🇽Monterrey, NL, Mexico
Centro de Estudios Clinicos y Esp Medicas SC
🇲🇽Monterrey, Nuevo Leon, Mexico
Emotional Brain B.V.
🇳🇱Almere, Netherlands
Amphia Ziekenhuis
🇳🇱Breda, Netherlands
Clinsante Centrum Medyczne
🇵🇱Torun, Poland
Cardinal Tien Hospital
🇨🇳Sindian City, Taipei County, Taiwan
Hospital de Braga
🇵🇹Braga, Portugal
Royal Devon and Exeter Hospital
🇬🇧Exeter, Devon, United Kingdom
Re-Cognition Health Ltd
🇬🇧London, United Kingdom
IRCCS Santa Lucia
🇮🇹Roma, Italy
Neuro-Pain Medical Center
🇺🇸Fresno, California, United States
St Josephs Hospital and Medical Center
🇺🇸Phoenix, Arizona, United States
Center for Neurosciences
🇺🇸Tucson, Arizona, United States
NEA Baptist Clinical
🇺🇸Jonesboro, Arkansas, United States
The Research Center of Southern California
🇺🇸Carlsbad, California, United States
Neurology Center of North Orange County
🇺🇸Fullerton, California, United States
WCCT Global
🇺🇸Costa Mesa, California, United States
Syrentis Clinical Research
🇺🇸Santa Ana, California, United States
Associated Neurologists, PC - Danbury
🇺🇸Danbury, Connecticut, United States
Morton Plant Hospital
🇺🇸Clearwater, Florida, United States
JEM Research Institute
🇺🇸Atlantis, Florida, United States
Indago Research & Health Center, Inc.
🇺🇸Hialeah, Florida, United States
Infinity Clinical Research, LLC
🇺🇸Hollywood, Florida, United States
Georgia Regents University
🇺🇸Augusta, Georgia, United States
Jacksonville Center for Clinical Research
🇺🇸Jacksonville, Florida, United States
Charlotte Neurological Services
🇺🇸Port Charlotte, Florida, United States
American Health Network
🇺🇸Muncie, Indiana, United States
Advanced Clinical Research LLC
🇺🇸Meridian, Idaho, United States
Via Christi Research, Inc.
🇺🇸Wichita, Kansas, United States
Cotton O'Neil Clinic
🇺🇸Topeka, Kansas, United States
University of Kansas Hospital
🇺🇸Fairway, Kansas, United States
Hattiesburg Clinic
🇺🇸Hattiesburg, Mississippi, United States
Clinical Research Professionals
🇺🇸Saint Louis, Missouri, United States
Butler Hospital
🇺🇸Providence, Rhode Island, United States
Las Vegas Medical Research
🇺🇸Las Vegas, Nevada, United States
New York University Medical Center
🇺🇸New York, New York, United States
Behavioral Health Center Research
🇺🇸Charlotte, North Carolina, United States
Advanced Memory Research Institute of New Jersey
🇺🇸Toms River, New Jersey, United States
Neurology Specialists of Monmouth County
🇺🇸West Long Branch, New Jersey, United States
Rapid Medical Research Inc
🇺🇸Cleveland, Ohio, United States
Rhode Island Mood & Memory Research Institute
🇺🇸East Providence, Rhode Island, United States
The Corvallis Clinic P.C.
🇺🇸Corvallis, Oregon, United States
Holston Medical Group Clinical Research
🇺🇸Kingsport, Tennessee, United States
Univ of North Texas Health Science Center
🇺🇸Fort Worth, Texas, United States
Recherches Neuro-Hippocampe Inc
🇨🇦Gatineau, Quebec, Canada
Toronto Memory Program
🇨🇦Toronto, Ontario, Canada
Beijing 301 Hospital
🇨🇳Beijing, Beijing, China
The Medical Arts Health Research Group
🇨🇦West Vancouver, British Columbia, Canada
Xuanwu Hospital-Capital Medical University
🇨🇳Beijing, Beijing, China
Douglas Hospital and Research Centre
🇨🇦Verdun, Quebec, Canada
Q&T Research Sherbrooke Inc
🇨🇦Sherbrooke, Quebec, Canada
Medical Services Prague s.r.o.
🇨🇿Praha 6, Czechia
Nanjing Drum Tower Hosp Affiliated Hosp of Nanjing Univ Med
🇨🇳Nanjing, Jiangsu, China
Shanghai Tongji Hospital(CCBR site)
🇨🇳Shanghai, Shanghai, China
Tangshan Worker Hospital
🇨🇳Tangshan, Hebei, China
Zhongda Hospital-Southeast University
🇨🇳Nanjing, Jiangsu, China
CHU Saint Etienne - Hopital Nord
🇫🇷Saint Priest en Jarez, Loire, France
CHU de Caen Hopital Cote de Nacre
🇫🇷Caen Cedex, France
APHM Hôpital de la Timone
🇫🇷Marseille, France
Diakoniekrankenhaus Henriettenstiftung Hannover
🇩🇪Hannover, Niedersachsen, Germany
Praxis Dr. Erich Scholz
🇩🇪Böblingen, Baden-Württemberg, Germany
A-Shine s.r.o.
🇨🇿Plzen, Czechia
CHU Rennes/Hopital Sud
🇫🇷Rennes Cedex, Ille Et Vilaine, France
CHU d'Amiens-Picardie Hopital Sud
🇫🇷Amiens Cedex 1, France
Rigshospitalet
🇩🇰Copenhagen, Denmark
CHU Strasbourg Hôpital de Hautepierre
🇫🇷Strasbourg Cedex, France
Neuropraxis München Süd
🇩🇪Unterhaching, Bayern, Germany
MVZ LiO Berlin
🇩🇪Berlin, Germany
Ente Ospedaliero Ospedali Galliera
🇮🇹Genova, Italy
Azienda Ospedaliera - Universitaria Pisana
🇮🇹Pisa, Italy
Nagoya Ekisaikai Hospital
🇯🇵Nagoya-shi, Aichi-Ken, Japan
Kojunkai Daido Hospital
🇯🇵Nagoya-Shi, Aichi-Ken, Japan
Koseikai Kusatsu Hospital
🇯🇵Hiroshima-shi, Hiroshima-Ken, Japan
Azienda Ospedaliera Citta della Salute della Scienza Torino
🇮🇹Torino, Italy
Universita La Sapienza
🇮🇹Roma, Italy
Inage Neurology and Memory Clinic
🇯🇵Chiba-shi, Chiba-Ken, Japan
Jisenkai Nanko Psychiatric Institute
🇯🇵Shirakawa-shi, Fukushima-Ken, Japan
Uji Takeda Hospital
🇯🇵Uji-Shi, Kyoto-Fu, Japan
Ehime University Hospital
🇯🇵Toon-Shi, Ehime-Ken, Japan
JADECOM Nara City Hospital
🇯🇵Nara-Shi, Nara-Ken, Japan
Takeda General Hospital
🇯🇵Aizu-Wakamatsu, Fukushima, Japan
NHO Hiroshima-Nishi Medical Center
🇯🇵Otaki-Shi, Hiroshima-Ken, Japan
Koseikai Takeda Hospital
🇯🇵Kyoto-Shi, Kyoto-Fu, Japan
Shimizu Hospital
🇯🇵Shizuoka-shi, Shizuoka, Japan
Yokohama Hospital
🇯🇵Yokohama, Kanagawa, Japan
Kousaiin Hospital
🇯🇵Suita-shi, Osaka-Fu, Japan
Oita University Hospital
🇯🇵Yufu-shi, Oita-Ken, Japan
Musashino Red Cross Hospital
🇯🇵Musashino, Tokyo, Japan
Keikokai P-One Clinic
🇯🇵Hachioji-shi, Tokyo-To, Japan
Inha University Hospital
🇰🇷Incheon, Korea, Republic of
JOHAS Sanin Rosai Hospital
🇯🇵Yonago-shi, Tottori-Ken, Japan
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Gyeonggi-do, Korea, Republic of
Hospital Univ. Jose Eleuterio Gonzalez
🇲🇽Monterrey, N.l., Mexico
Hanyang University Medical Center
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Isala Klinieken
🇳🇱Zwolle, Netherlands
Podlaskie Centrum Psychogeriatrii
🇵🇱Białystok, Podlaskie, Poland
Brain Research Center
🇳🇱Amsterdam, Netherlands
NZOZ Mach-Med
🇵🇱Chorzow, Poland
Globe Badania Kliniczne SP Z O.O.
🇵🇱Klodzko, Poland
Prywatny Gabinet Lekarski U.Chyrchel
🇵🇱Lublin, Poland
Centrum Medyczne Medyk
🇵🇱Rzeszow, Poland
Euromedis Sp. z o.o.
🇵🇱Szczecin, Poland
Hospitals da Universidade de Coimbra
🇵🇹Coimbra, Portugal
SAIH Republ. Clinical Hospital of the MoH of Republ. Tatarst
🇷🇺Kazan, Russian Federation
Centrum Medyczne
🇵🇱Warszawa, Poland
Specjalistyczny Osrodek Medycyny Wieku Dojrzalego SOMED
🇵🇱Warszawa, Poland
Hospital Fernando Fonseca
🇵🇹Amadora, Portugal
SIH Kemerovo Regional Clinical Hosptial
🇷🇺Kemerovo, Russian Federation
Hospital Cardiovascular San Vicente
🇪🇸San Vicente del Raspeig, Alicante, Spain
LLC City Neurological Centre Sibneuromed
🇷🇺Novosibirsk, Russian Federation
LLC Treatment and Rehabilitation
🇷🇺Rostov-on-Don, Russian Federation
Hospital General de Catalunya
🇪🇸Sant Cugat del Valles, Barcelona, Spain
Novosibirsk State Medical University
🇷🇺Novosibirsk, Russian Federation
Hospital Ntra Sra Perpetuo Socorro
🇪🇸Albacete, Spain
Bekhterev Psyconeurological Institute
🇷🇺St. Petersburg, Russian Federation
Central Medical Sanitary Hospital #122
🇷🇺St. Petersburg, Russian Federation
Regional State Institution of Healthcare Tomsk Clinica Psych
🇷🇺Tomsk, Russian Federation
National Taiwan University Hospital
🇨🇳Douliu, Yunlin County, Taiwan
Chang Gung Memorial Hospital - Linkou
🇨🇳Taoyuan City, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Hospital del Mar
🇪🇸Barcelona, Spain
Policlinica Guipuzcoa
🇪🇸Donostia, Guipuzcoa, Spain
Fundacion ACE-Institut Catala de Neurociences Aplicades
🇪🇸Barcelona, Spain
Kaohsiung Medical University Chung-Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
Chang Gung Memorial Hospital - Kaohsiung
🇨🇳Kaohsiung, Taiwan
Taipei Medical University- Shuang Ho Hospital
🇨🇳New Taipei, Taiwan
Victoria Centre
🇬🇧Swindon, Wiltshire, United Kingdom
Glasgow Memory Clinic
🇬🇧Glasgow, United Kingdom
Lynn Health Science Institute
🇺🇸Oklahoma City, Oklahoma, United States
Cutting Edge Research Group
🇺🇸Oklahoma City, Oklahoma, United States
Summit Research Network Inc
🇺🇸Portland, Oregon, United States
Murray Royal Hospital
🇬🇧Perth, Tayside Region, United Kingdom
Axiom Research
🇺🇸Tampa, Florida, United States
University of South Florida
🇺🇸Tampa, Florida, United States
Hospital Universitario La Fe de Valencia
🇪🇸Valencia, Spain
Institute for Neurodegenerative Disorders
🇺🇸New Haven, Connecticut, United States
Compass Research
🇺🇸Orlando, Florida, United States
Yale University School of Medicine
🇺🇸New Haven, Connecticut, United States
PMG Research of Winston-Salem, LLC
🇺🇸Winston-Salem, North Carolina, United States
Wake Forest Baptist Univ CAR
🇺🇸Winston-Salem, North Carolina, United States
Arizona Neurology
🇺🇸Scottsdale, Arizona, United States
Pacific Neuroscience Medical Group
🇺🇸Oxnard, California, United States
Pearl Clinical Research Inc.
🇺🇸Norristown, Pennsylvania, United States
Insight Clinical Trials
🇺🇸Shaker Heights, Ohio, United States
Clinical Trial Center, LLC, Psychiatry
🇺🇸Jenkintown, Pennsylvania, United States
Guangzhou First People's Hospital
🇨🇳Guangzhou, Guangdong, China
Qingdao Municipal Hospital
🇨🇳Qingdao, Shandong, China
Northern Jiangsu People's Hospital
🇨🇳Yangzhou, Jiangsu, China
Shanghai Huashan Hospital Affil to Fu Dan University
🇨🇳Shanghai, China
The First Affiliated Hospital of Wenzhou Medical College
🇨🇳Wenzhou, Zhejiang, China
West China Hospital of Sichuan University
🇨🇳Chengdu, Sichuan, China
The First Affiliated Hospital, Zhejiang University
🇨🇳Hangzhou, Zhejiang, China
Fakultni nemocnice u sv. Anny v Brne
🇨🇿Brno, Czechia
Neurohk s.r.o.
🇨🇿Chocen, Czechia
Brain-Soultherapy s.r.o
🇨🇿Kladno, Czechia
Neuropsychiatrie s.r.o
🇨🇿Praha 6, Czechia
Axon Clinical, s.r.o.
🇨🇿Praha 8, Czechia
CCBR-Alborg-DK
🇩🇰Aalborg, Denmark
Clintrial, s.r.o.
🇨🇿Praha 10, Czechia
Center for Clinical and Basic Research -CCBR
🇩🇰Vejle, Denmark
Center For Clinical and Basic Research
🇩🇰Ballerup, Denmark
Chu de Toulouse Hopital de La Grave
🇫🇷Toulouse Cedex, France
ISPG - Institut für Studien zur psychischen Gesundheit
🇩🇪Mannheim, Baden-Württemberg, Germany
Spedali Civili - Universita degli Studi
🇮🇹Brescia, Italy
Azienda Ospedaliera Universitaria Careggi
🇮🇹Firenze, Italy
Shinwakai Yachiyo Hospital
🇯🇵Anjo-shi, Aichi-Ken, Japan
Yuge Hospital
🇯🇵Kumamoto, Japan
Accelerium Clinical Research
🇲🇽Monterrey, Nuevo Leon, Mexico
Hawaii Medical Center
🇺🇸Honolulu, Hawaii, United States
Baptist Health Medical Group
🇺🇸Lexington, Kentucky, United States
Associates in Neurology, PSC
🇺🇸Lexington, Kentucky, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
SSM Health Dean Medical Group
🇺🇸Madison, Wisconsin, United States
Bruyere Continuing Care
🇨🇦Ottawa, Ontario, Canada
Coastal Neurology PA
🇺🇸Port Royal, South Carolina, United States
Hôpital de la Pitié-Salpêtrière
🇫🇷Paris, France
Hospital Mutua de Terrassa
🇪🇸Terrassa, Barcelona, Spain
Hospital Virgen Del Puerto
🇪🇸Plasencia, Caceres, Spain
Rhode Island Hospital
🇺🇸Providence, Rhode Island, United States
Radiant Research
🇺🇸Greer, South Carolina, United States